The therapeutic landscape of tauopathies: challenges and prospects-Reference-Cited by-同舟云学术

The therapeutic landscape of tauopathies: challenges and prospects

Published:2023-10-06 Issue:1 Volume:15 Page:
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alz Res Therapy

Author:

Cummings Jeffrey L.,Gonzalez M. Isabel,Pritchard Martyn C.,May Patrick C.,Toledo-Sherman Leticia M.,Harris Glenn A.

Abstract

AbstractTauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal death, which leads to a range of symptoms including cognitive decline, behavioral change, dementia, and motor deficits. Currently, there are no effective treatments for tauopathies. There are four clinical candidates in phase III trials and 16 in phase II trials. While no effective treatments are currently approved, there is increasing evidence to suggest that various therapeutic approaches may slow the progression of tauopathies or improve symptoms. This review outlines the landscape of therapeutic drugs (indexed through February 28, 2023) that target tau pathology and describes drug candidates in clinical development as well as those in the discovery and preclinical phases. The review also contains information on notable therapeutic programs that are inactive or that have been discontinued from development.

Funder

Rainwater Charitable Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cognitive Neuroscience,Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1186/s13195-023-01321-7.pdf

Reference98 articles.

1. Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, Meyfour A, Sheriff S, Shen T, Dhiman K, Salekdeh GH, Haynes PA, Graham SL, Mirzaei M. Comparative analysis of aducanumab, zagotenemab and pioglitazone as targeted treatment strategies for Alzheimer’s disease. Aging Dis. 2021;12(8):1964. https://doi.org/10.14336/AD.2021.0719.

2. Alosco ML, Su Y, Stein TD, Protas H, Cherry JD, Adler CH, Balcer LJ, Bernick C, Pulukuri SV, Abdolmohammadi B, Coleman MJ, Palmisano JN, Tripodis Y, Mez J, Rabinovici GD, Marek KL, Beach TG, Johnson KA, Huber BR, … Johnson KA. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players. Eur J Nuclear Med Mol Imaging. 2023;50(2):435–452 https://doi.org/10.1007/s00259-022-05963-x.

3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3):631–631. https://doi.org/10.1212/WNL.42.3.631.

4. Bejanin A, Schonhaut DR, la Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O’Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain. 2017;140(12):3286–300. https://doi.org/10.1093/brain/awx243.

5. Bendstrup N, Hejl A-M, Salvesen L. Neurofilament light chain levels in frontotemporal dementia and progressive supranuclear palsy: a systematic review. J Alzheimer’s Dis. 2022;87(1):131–40. https://doi.org/10.3233/JAD-215616.